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A recently returned award-winning
medical scientist is stirring major
excitement in South Africa with a
pharmacogenetic approach to drug
therapy in general, and to AIDS in
particular. The latter has the potential to
radically reduce drug-resistant strains of
the HIV virus through viral genome
sequencing.
Some development of drug-resistant
strains in the HIV-positive population is
considered inevitable in spite of the best
managed antiretroviral roll-out systems
because of South Africa’s demographics,
infrastructure, and lack of human
resource capacity.
Vital significance
The cost to the State of bulk supplies of
second-generation antiretroviral drugs
would be huge and has been the subject
of fierce debate around the current
preparedness for and pace of the drugs
roll-out. This confers vital significance
on the work of University of Cape Town
medical graduate, Professor Michael
Pepper, who recently joined the
Witwatersrand School of Anatomical
Sciences from the University of Geneva. 
Pepper stirred major interest at a
Roche Diagnostics In Vitro forum in
Johannesburg in October by, among
other things, suggesting that in the not
too distant future a failure to genotype
patients before any treatment could be
considered unethical.
In his presentation, Pepper said that
useful South African statistics for
adverse drug reactions (ADR) were
absent. However, in the USA 100 000
people died annually from ADR and
more than two million hospital patients
experienced ADR every year.
United Kingdom statistics showed
ADR to be costing R3.8 billion per
annum, with 7% of all patients affected.
ADR accounted for an estimated 10%
of National Health Service (UK) bed
days while chemotherapy ADRs
increased overall drug costs by 15%.
Financial backing
At the time of writing, Roche
Diagnostics were in the process of
setting up a multi-million rand cutting-
edge molecular diagnostics research
platform for Pepper.
He is due to brush up on some
technology in the USA before beginning
his research in earnest this year.
It will be South Africa’s first public-
private partnership in this area. While
genotyping and resistance testing is
some way off, Pepper’s current work
centres on drug toxicity and therapeutic
levels – how the patient metabolises the
drug and the implications this has for
medicine. He told the Johannesburg
diagnostics forum that educating health
care professionals about rapidly
evolving molecular technology
including the human genome was
essential so that it could be incorporated
into clinical practice as soon as
practically possible.
Pepper told Izindaba that a great deal
of work had been done on viral
resistance, especially around relating
mutations of the HIV genome directly
to different kinds of drugs. However,
‘very little’ work around therapy had
been done on the patient genome.
Asked when he thought his work might
begin to have direct benefit, Pepper
said, with typical scientific caution,
‘that’s impossible to answer right now.’
He explained that sequencing the
viral genome enabled scientists to tell
whether a particular virus would
become resistant. Mutations in the drug
targets in the virus were predictors of
whether there would be resistance or
not. ‘Practically, you take a blood
sample and when you do the viral load
you take some DNA from the virus and
perform the sequencing in any one of a
number of ways’.
Pepper said there had been
‘enormous excitement at universities
and in the public and private pathology
sectors’. He said that two genes, the
reverse transcriptase gene and the
protease gene, underwent a large
number of mutations, often in response
to sub-optimal treatment, which
conferred resistance to some of the
AIDS drugs.
‘These are the things we’d want to
sequence and, depending on the
mutations in these genes, we’d be able
to predict to which drugs the virus
would be resistant,’ he said. This was
done through algorithms that were
constantly updated in public databases.
He added that the ‘other side of the
coin’ was to examine the patient to see
whether or not they would respond to
antiretroviral and other drugs used in
the treatment of the complications of
AIDS. Many of these drugs, including
antiretrovirals, caused severe and
sometimes life-threatening side-effects.
Slow and fast metabolisers
People metabolise drugs at different
rates. For slow metabolisers there could
be a therapeutic effect but a greater risk
of toxicity, whereas rapid metabolisers
PHARMACOGENETICS OFFERS HOPE
Professor Michael Pepper of the Wits School of
Anatomical Sciences.
The departure of Peter Roberts, head of
our Health and Medical Publishing
Group (HMPG) this December after 20
years of forging it into a highly
successful operation has become the
catalyst for an exciting and creative
realignment.
The core business of the HMPG is to
produce 17 periodic medical
publications in about 100 editions
annually with content generation by a
highly skilled and experienced editorial
team. This team will remain directly
accountable to the South African
Medical Association (SAMA).
However, with some lateral thinking,
a deal has emerged in which the HMPG
business team (production, marketing,
advertising, distribution) will partner
Andrew Fehrsen, founder and MD of
one of the country’s largest business to
business publishing houses, Cape
Media.
Replacing institutional memory and
specialist hands-on ability like that
which Roberts has was never going to
be an easy task, yet the current deal will
open even more doors and optimise the
HMPG operation.
Fehrsen, who has created over 100
jobs in Cape Media over the past 6
years, said at a ceremony to sign the
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might fail to achieve therapeutic levels
while facing a negligible toxicity risk.
Pepper said work on the human
genome would take far longer, ‘because
we don’t yet know enough about the
metabolism of antiretrovirals’.
Meanwhile Roche’s AmpliChip
CYP450 test, which analyses variations
in two genes that play a major role in
the metabolism of almost half of all
drugs currently on the market, received
the CE mark (‘Conformité Européene’),
allowing the test to be used for
diagnostic purposes in the European
Union.
The test detects genetic variations in
the cytochrome P450 2D6 and 2C19
genes and provides the associated
predictive phenotype (poor,
intermediate, extensive, or ultra-rapid
metaboliser). Results can be used by
physicians as an aid for selecting drugs
and individualising treatment doses for
drugs primarily metabolised by the
enzymes these genes encode. 
Roche Diagnostics chief, Heino von
Prondzynski, described the test as the
first representative of an exciting new
technology that held great potential for
diagnostic applications.
The AmpliChip CYP450 test uses two
industry gold standards, Roche
polymerase chain reaction (PCR)
amplification technology and
Affymetrix high-density microarray
technology (glass chips arrayed with
tens of thousands of DNA fragments yet
no bigger than a thumbnail). The
latter’s GeneChip System 3000Dx
instrumentation, on which the
AmpliChip is run, has also been CE
marked.
Enzymes encoded by the CYP2D6
gene metabolise many antidepressants,
antipsychotics, anti-arrhythmics, pain
drugs, antiemetics, and beta-blockers
(beta-adrenergic receptor blocker
drugs). Enzymes encoded by the
CYP2C19 gene metabolise drugs from a
variety of classes, including
anticonvulsants, proton pump
inhibitors, anticoagulants, benzodia-
zepines, and antimalarials.
With AIDS, this new technology may
only be useful for assessing the genetics
of the patient’s ability to metabolise
antiretrovirals and other drugs used in
the treatment of this disease. 
Pepper said one indication of the
‘Machiavellian nature’ of HIV/AIDS,
was that the virus mutated at a rate that
was too quick for AmpliChip
technology to be of use. The Chips were
updated every 2 years, which did not
allow for new mutations to be included
in a timeous manner. He said other
molecular techniques that could be
adapted in a very short space of time to
detect for novel mutations, would have
to be used.
Pepper is a holder of the Walter Johnson
award for post-doctoral research in cell
biology (1974) and the prestigious Denber
Pinard award for his Privat Docent Thesis
(1977).
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SHOT IN THE ARM FOR SAMA PUBLISHING
SAMA Secretary General, Dr Moji Mogare,
signs the new HMPG deal with Cape Media
founder, Andrew Fehrsen.
Cape Media founder and new HMPG partner,
Andrew Fehrsen, with Deputy Editor of the
SAMJ, Professor JP van Niekerk.
